BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

...Raj Manchanda to chief development officer after serving as Anokion’s chief technical operations officer since 2019.GlycoMimetics Inc....
...& Johnson (NYSE:JNJ) subsidiary. Osborne was head of manufacturing operations at ADC Biotechnology Ltd. BC Staff Anokion S.A. GlycoMimetics Inc. Lava...
BioCentury | Nov 7, 2020
Finance

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

...to APL-106 (uproleselan) and APL-108 (GMI-1687) from GlycoMimetics Inc....
...mainland China, Hong Kong, Macau and Taiwan. GlycoMimetics...
BioCentury | Nov 4, 2020
Politics, Policy & Law

Warp Speed co-leader Slaoui signs letter supporting Fauci

...Therapeutics Inc. (NASDAQ:NKTX); Rachel King, CEO of GlycoMimetics Inc....
...Therapeutics Inc. Nkarta Inc. Global Blood Therapeutics Inc. Acorda Therapeutics Inc. GlycoMimetics Inc. Alnylam...
BioCentury | Sep 3, 2020
Product Development

BIO leaders urge industry to hew to norms for COVID-19 candidates

...Inc. (NASDAQ:ACOR); King is founder and CEO of GlycoMimetics Inc....
BioCentury | Feb 20, 2020
Politics, Policy & Law

Pharma execs speak out against 'misuse' of Orphan status as another old therapy sees a price hike

...NASDAQ:ACOR); John Crowley, chairman and CEO of Amicus Therapeutics Inc. (NASDAQ:FOLD); Rachel King, CEO of GlycoMimetics Inc....
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...pneumococcal disease. Pfizer ends deal with GlycoMimetics Pfizer Inc. (NYSE:PFE) terminated its 2011 deal with GlycoMimetics Inc....
...a Phase III trial to treat sickle cell disease in August (see “Next up for GlycoMimetics”...
BioCentury | Jan 8, 2020
Politics, Policy & Law

Over 200 biopharma leaders endorse commitment to patients and the public

...and CEO, Amicus Therapeutics Inc. (NASDAQ:FOLD); Paul Hastings, CEO, Nkarta Therapeutics Inc.; Rachel King, CEO, GlycoMimetics...
...other potentially curative medicines. “Each company is going to have to make their case drug-by-drug,” Glycomimetics...
...and ensuring people have access to it.” Steve Usdin, Washington Editor Johnson & Johnson Biocon Ltd. Amicus Therapeutics Inc. Nkarta Inc. GlycoMimetics Inc. Alnylam...
BioCentury | Jan 7, 2020
Company News

Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more

...to uproleselan and GMI-1687 from GlycoMimetics Inc. (NASDAQ:GLYC) in mainland China, Hong Kong, Macau and Taiwan. GlycoMimetics...
...Anti-PD-L1) Forxiga (Brand), Farxiga (Brand), BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Pfizer Inc. Merck KGaA AstraZeneca plc Sanofi Apollomics Inc. GlycoMimetics Inc. Anaplastic...
BioCentury | Nov 11, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...red blood cells (RBCs) and inflammation in patient vasculature, including the pan-selectin antagonist rivipansel from GlycoMimetics Inc....
BioCentury | Nov 9, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...red blood cells (RBCs) and inflammation in patient vasculature, including the pan-selectin antagonist rivipansel from GlycoMimetics Inc....
Items per page:
1 - 10 of 134
BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

...Raj Manchanda to chief development officer after serving as Anokion’s chief technical operations officer since 2019.GlycoMimetics Inc....
...& Johnson (NYSE:JNJ) subsidiary. Osborne was head of manufacturing operations at ADC Biotechnology Ltd. BC Staff Anokion S.A. GlycoMimetics Inc. Lava...
BioCentury | Nov 7, 2020
Finance

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

...to APL-106 (uproleselan) and APL-108 (GMI-1687) from GlycoMimetics Inc....
...mainland China, Hong Kong, Macau and Taiwan. GlycoMimetics...
BioCentury | Nov 4, 2020
Politics, Policy & Law

Warp Speed co-leader Slaoui signs letter supporting Fauci

...Therapeutics Inc. (NASDAQ:NKTX); Rachel King, CEO of GlycoMimetics Inc....
...Therapeutics Inc. Nkarta Inc. Global Blood Therapeutics Inc. Acorda Therapeutics Inc. GlycoMimetics Inc. Alnylam...
BioCentury | Sep 3, 2020
Product Development

BIO leaders urge industry to hew to norms for COVID-19 candidates

...Inc. (NASDAQ:ACOR); King is founder and CEO of GlycoMimetics Inc....
BioCentury | Feb 20, 2020
Politics, Policy & Law

Pharma execs speak out against 'misuse' of Orphan status as another old therapy sees a price hike

...NASDAQ:ACOR); John Crowley, chairman and CEO of Amicus Therapeutics Inc. (NASDAQ:FOLD); Rachel King, CEO of GlycoMimetics Inc....
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...pneumococcal disease. Pfizer ends deal with GlycoMimetics Pfizer Inc. (NYSE:PFE) terminated its 2011 deal with GlycoMimetics Inc....
...a Phase III trial to treat sickle cell disease in August (see “Next up for GlycoMimetics”...
BioCentury | Jan 8, 2020
Politics, Policy & Law

Over 200 biopharma leaders endorse commitment to patients and the public

...and CEO, Amicus Therapeutics Inc. (NASDAQ:FOLD); Paul Hastings, CEO, Nkarta Therapeutics Inc.; Rachel King, CEO, GlycoMimetics...
...other potentially curative medicines. “Each company is going to have to make their case drug-by-drug,” Glycomimetics...
...and ensuring people have access to it.” Steve Usdin, Washington Editor Johnson & Johnson Biocon Ltd. Amicus Therapeutics Inc. Nkarta Inc. GlycoMimetics Inc. Alnylam...
BioCentury | Jan 7, 2020
Company News

Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more

...to uproleselan and GMI-1687 from GlycoMimetics Inc. (NASDAQ:GLYC) in mainland China, Hong Kong, Macau and Taiwan. GlycoMimetics...
...Anti-PD-L1) Forxiga (Brand), Farxiga (Brand), BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Pfizer Inc. Merck KGaA AstraZeneca plc Sanofi Apollomics Inc. GlycoMimetics Inc. Anaplastic...
BioCentury | Nov 11, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...red blood cells (RBCs) and inflammation in patient vasculature, including the pan-selectin antagonist rivipansel from GlycoMimetics Inc....
BioCentury | Nov 9, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...red blood cells (RBCs) and inflammation in patient vasculature, including the pan-selectin antagonist rivipansel from GlycoMimetics Inc....
Items per page:
1 - 10 of 134